China Renaissance acted as exclusive financial advisor for Ascentage. On December 22, 2016, the U.S. Food and Drug Administration (FDA) granted Investigational New Drug (IND) approval to APG-1252, a novel Bcl-2/Bcl-x L inhibitor which is discovered and developed by Ascentage, for the treatment of cancers including Small Cell Lung Cancer (SCLC). APG-1252 is a small molecule drug that helps restore programmed cell death process (apoptosis) through selective inhibition of Bcl-2 family members Bcl-2 and Bcl-x L. Rationally designed to avoid the commonly seen on-target toxicity in platelets when Bcl-x L gets inhibited, APG-1252 is of best-in-class potential. The pre-clinical data shows that the compound remains strong anti-tumor potency while exhibiting minimal toxicity in platelets.